Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukemia cells with multidrug resistance

R Pincus1, I D Goldman

  • 1Department of Medicine, Medical College of Virginia, Richmond 23298.

Biochemical Pharmacology
|December 15, 1990
PubMed

Insights

Multidrug resistance (MDR) in cancer cells involves reduced drug binding. This study shows decreased intracellular binding of mitoxantrone and vinblastine significantly impacts drug accumulation and retention in resistant P388 leukemia cells.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) limits chemotherapy efficacy.
  • The P170 glycoprotein efflux pump is implicated in MDR.
  • Decreased drug binding may also contribute to MDR.

Purpose of the Study:

  • To investigate the role of altered intracellular drug binding in MDR.
  • To assess the contribution of binding differences to drug accumulation and retention in MDR cells.

Main Methods:

  • Studied mitoxantrone and vinblastine in P388 murine leukemia cells.
  • Compared drug binding and accumulation in sensitive versus MDR cell lines.

Main Results:

  • Resistance was linked to significantly reduced tightly bound (nonexchangeable) fractions of both drugs.
  • Mitoxantrone's exchangeable fraction was higher at low concentrations and similar at high concentrations in resistant cells.
  • Vinblastine's exchangeable fraction decreased at low concentrations but was similar at high concentrations in resistant cells.

Conclusions:

  • Diminished intracellular binding, specifically reduced nonexchangeable drug fractions, is a key factor in decreased drug uptake and retention in MDR cells.
  • Altered drug binding contributes significantly to the multidrug resistance phenomenon.
  • Further research is needed to clarify the link between binding changes and the P170 efflux pump.